Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients

B. Rubio-Viqueira, M. Hidalgo

Research output: Contribution to journalReview articlepeer-review

Abstract

It is estimated that the development of a new anticancer agent costs US$800 million to 1 billion and takes more than a decade between conception and approval. However, 90% of novel antineoplastic drugs fail in the clinic despite evidence of antitumor efficacy in classical preclinical models. This raises serious concerns as to whether such models are predictive of drug efficacy in humans, particularly in the current era of new targeted therapies, and supports the development of alternative approaches.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalClinical pharmacology and therapeutics
Volume85
Issue number2
DOIs
StatePublished - Feb 1 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients'. Together they form a unique fingerprint.

Cite this